Neurogene Inc.NGNENASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's webs.

businesswire.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,450 shares of the Company's common stock to four new employees (the “Inducement Grants”) on March 2, 2026 (the “Grant Date”). The Inducem.

247wallst.com

Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More

Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts' earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the... Here Are Friday's Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More.

businesswire.com

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, an investigational gene therapy in late-stage clinical development as a potential best-in-class treatment for Rett syndrome. The Breakthrough Therapy designation was based on the F.

defenseworld.net

Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Average Price Target from Analysts

Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the

defenseworld.net

Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene (NASDAQ: NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim's 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a "devastating neurologic disease" that primarily affects girls. She said children often show developmental

businesswire.com

Neurogene to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference F.

businesswire.com

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the “Inducement Grant”) on February 2, 2026 (the “Grant Date”). The Induceme.

defenseworld.net

Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50

Neurogene Inc. (NASDAQ: NGNE - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year

businesswire.com

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for multiple value-creating catalysts anticipated in 2026. “We are pleased to share that multiple participants have been dosed in our Embolden registrational trial of NGN-401 gene ther.

businesswire.com

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference. Format: Management will present a company overview and participate in investor meetings Date: Wednesday, January 14 at 7:30 a.m. PT A webcast of the presentation will be accessible from the I.

businesswire.com

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of the Company's common stock to two new employees (the “Inducement Grants”) on December 2, 2025 (the “Grant Date”). The Induce.

seekingalpha.com

Neurogene: From Speculation To Execution With NGN-401

Neurogene has transitioned into a data-driven, registrational-stage company with NGN-401 showing strong safety and efficacy for Rett syndrome. NGNE's disciplined financial management provides a cash runway through Q1 2028, allowing focused investment in its lead asset and minimizing dilution risk. NGN-401's clinical data demonstrate durable, multi-domain functional gains and a favorable safety profile, positioning it as a potential first-in-class therapy.

businesswire.com

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2025 financial results and highlighted recent corporate updates. “We significantly advanced our NGN-401 gene therapy clinical program for Rett syndrome over the past quarter, culminating in the recent dosing of the first participant in the Embolden registrational trial af.

seekingalpha.com

Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript

Neurogene Inc. ( NGNE ) Stifel 2025 Healthcare Conference November 12, 2025 4:40 PM EST Company Participants Rachel McMinn - Founder, Executive Chair & CEO Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Paul Matteis Stifel, Nicolaus & Company, Incorporated, Research Division Thank you very much. Happy to be introducing Rachel McMinn, Founder and CEO of Neurogene, who has some new fresh data to talk us through for NGN-401 in Rett syndrome.

businesswire.com

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive, updated interim clinical data in the pediatric cohort (ages 4-10 cohort) from its ongoing Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. “Updated interim data from our Phase 1/2 trial of NGN-401 show that all pediatric partici.

businesswire.com

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential to be a best-in-class and first-in-class gene therapy for Rett syndrome, a neurodevelopmental diso.

businesswire.com

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 1,185 shares of the Company's common stock to one new employee (the “Inducement Grant”) on November 4, 2025 (the “Grant Date”). The Induceme.

businesswire.com

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the Company has completed discussions with the U.S. Food and Drug Administration (FDA) on its Embolden™ registrational trial protocol and plans to initiate dosing in the fourth quarter of 2025. In response to strong interest from the Rett syndrome community, the trial is expected to en.

businesswire.com

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Invest.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance